GlassScriptPhysician profile
Damaris Caraballo
NPI 1245708809
$729.41
in general payments reported to CMS, 2019-2025
12 companies · $28.95 in 2025
The $28.95 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.63 · 2022: $264 · 2023: $190 · 2024: $150 · 2025: $28.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $213.74 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $118.65 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $92.02 | 2021-2023 | |
| Novo Nordisk INC | $90.68 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $60.16 | 2022-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.25 | 2021-2023 | Jardiance |
| Inspire Medical Systems, INC. | $28.95 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $24.13 | 2021 | |
| Exact Sciences Corporation | $23.73 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $17.00 | 2023 | |
| Almatica Pharma LLC | $15.00 | 2023 | Gralise, Loreev Xr |
| Astrazeneca Pharmaceuticals LP | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damaris Caraballo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.